Prelude Therapeutics (PRLD) Share-based Compensation (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Share-based Compensation data on file, last reported at $51000.0 in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 920.0% year-over-year to $51000.0; the trailing twelve-month figure through Mar 2026 stood at $8.1 million (down 48.54% YoY), and the FY2025 full-year result was $11.9 million, down 45.6% from the prior year.
• Share-based Compensation eased to $51000.0 in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.8 million in Q1 2022 to a low of $5000.0 in Q1 2025.
• A 5-year average of $4.7 million and a median of $5.9 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 99.91% in 2025 and surged 920.0% in 2026, its largest moves.
• Tracing PRLD's Share-based Compensation over 5 years: stood at $5.8 million in 2022, then advanced by 1.15% to $5.9 million in 2023, then sank by 36.16% to $3.8 million in 2024, then plunged by 51.14% to $1.8 million in 2025, then slumped by 97.23% to $51000.0 in 2026.
• Business Quant data shows PRLD's Share-based Compensation at $51000.0 in Q1 2026, $1.8 million in Q4 2025, and $2.4 million in Q3 2025.